**Data Sheet**

**Product Name:** Sertindole  
**Cat. No.:** HY-14543  
**CAS No.:** 106516-24-9  
**Molecular Formula:** C_{24}H_{26}ClF_{2}N_{2}O  
**Molecular Weight:** 440.94  
**Target:** 5–HT Receptor; Autophagy; Dopamine Receptor  
**Pathway:** Autophagy; GPCR/G Protein; Neuronal Signaling  
**Solubility:** 10 mM in DMSO

**BIOLOGICAL ACTIVITY:**

Sertindole, a neuroleptic, is one of the newer antipsychotic medications available.

Target: Multi–target  
In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5–HT2A, 5–HT2C, dopamine D2, and αl adrenergic receptors. Sertindole offers an alternative treatment option for refractory patients given its good EPS profile, favorable metabolic profile, and comparable efficacy to risperidone. Due to cardiovascular safety concerns, sertindole is available as a second–line choice for patients intolerant to other antipsychotic agents [1]. Sertindole should prove to be a very useful addition to the therapeutic options available for the treatment of psychotic disorders [2]. Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic–resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS). Thus, sertindole is a useful option in the treatment of patients with schizophrenia [3].

**References:**


---

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898  
Fax: 609-228-5909  
E-mail: tech@MedChemExpress.com  
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA